Dr Elisabeth Arrojo
Elisabeth Arrojo, founder of the Institute of Advanced Medical Oncology (Inmoa) and of the National Cancer Prevention Center in Spain, corresponding academic of the Academy of Sciences, Engineering and Humanities of Lanzarote and full member of the Royal European Academy of Doctors (READ), has been honored with the Madrid Association of Young Entrepreneurs Award as Best Young Businesswoman 2025 at the 21st edition of these prestigious awards. The prize also recognizes Inmoa’s contribution to the development of personalized medicine models, evidence-based complementary therapies, and structured cancer prevention programs.
As acknowledged by the jury, Arrojo leads from Madrid a project that integrates state-of-the-art oncological hyperthermia, advanced clinical monitoring, primary and secondary prevention programs, and health education for the general population and at-risk groups. Her approach is characterized by the application of validated, reproducible, and person-centered clinical methods, reinforcing the idea that the medicine of the future must offer effective tools before, during, and after diagnosis. In this regard, within a healthcare context in which prevention, early diagnosis, and precision therapies are transforming oncological practice, Inmoa incorporates advanced clinical technology, multidisciplinary teams, and a rigorous approach that combines science, innovation, and patient-centered care.
«Innovation makes sense when it improves people’s lives. This award reflects the work of a committed team and of every patient who inspires our scientific and human vocation,» the academic stated when expressing her gratitude for the recognition. The Madrid Association of Young Entrepreneurs, for its part, highlighted through this distinction the importance of business models that drive transformation in the healthcare sector through applied research, prevention, and young leadership in projects with high social impact.
The Institute of Advanced Oncology is a medical center specializing in advanced oncology, clinical hyperthermia, and preventive medicine, based in Madrid. Its mission is to integrate cutting-edge healthcare technologies and evidence-based complementary therapies in order to improve available therapeutic options and strengthen cancer prevention among the population. Inmoa combines precise diagnosis, prevention programs, and comprehensive care to offer a healthcare model that is more human, more rigorous, and more efficient. As for the National Cancer Prevention Center directed by Elisabeth Arrojo herself, it develops specific programs for primary and secondary prevention, personalized screening, and the promotion of healthy lifestyles. Its activity is aimed at reducing cancer incidence and improving prognosis through strategies based on scientific evidence, health education, and advanced clinical technology.
After earning her degree in Medicine and Surgery from the University of Navarra, where she was selected as the only resident student in the Department of Neurosurgery at the University Clinic of Navarra, she completed her specialty in Radiation Oncology, carrying out her clinical training at the Central Hospital of Asturias. She began her medical career at the Marqués de Valdecilla University Hospital, where she developed a pioneering technique for the treatment of breast cancer, managing to reduce the number of radiotherapy treatment sessions from 33 to a single outpatient session, which also reduces the radiation dose received by healthy tissues. The now-renowned oncologist later moved to Michigan to develop her professional career at the international oncology center 21st Century Oncology, where she served as research coordinator. For her work, she was recognized as an Extraordinary Person in the Sciences and received recognition from the American Brachytherapy Society.
Holding a PhD cum laude from the University of Oviedo with the dissertation «Urethral Protection in the Treatment of Prostate Cancer with Radiotherapy,» Arrojo has established herself as one of the leading experts in pain management and oncological nutrition and is the principal investigator of studies currently being conducted on oncothermia at both the Marqués de Valdecilla University Hospital and the Institute of Advanced Medical Oncology. In recent years, her research has earned her the National Prize for Medicine (2021), the European Prize for Medicine in the Oncology category (2021 and 2022), and the European Doctor Fleming Award for Excellence in Healthcare, among other prestigious distinctions.
